gdc
Breast CancerFDA Approvals, News & Updates

Kadcyla Approved for Adjuvant Treatment of HER2-Positive Early Breast Cancer with Residual Invasive Disease

June 2019 Vol 5 No 3

In May 2019, the FDA approved a new indication for Kadcyla (ado-trastuzumab emtansine; from Genentech) for adjuvant (additional) treatment of patients with HER2-positive early breast cancer and residual invasive disease after endocrine treatment with a taxane and Herceptin (trastuzumab). At the same time, the FDA approved 2 tests that should be used to select appropriate patients for adjuvant treatment with Kadcyla. Kadcyla was initially approved in 2013 for HER2-positive metastatic breast cancer.

This new approval was based on a clinical trial of 1486 patients with HER2-positive early breast cancer who received Kadcyla or Herceptin for a total of 14 cycles. After an average of 40 months, patients who received Kadcyla showed significant reduction in residual invasive disease versus those who received Herceptin. The most common side effects with Kad­cyla are fatigue, nausea, musculoskeletal and joint pain, bleeding, low platelet count, headache, and peripheral neuropathy.

Recommended For You
Breast Cancer
Pink Ribbons in October
By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
Welcome to our newest issue of CONQUER. We know the value of hearing the experiences of cancer survivors and family caregivers. It helps people to relate, feel a sense of connection, and provides food for thought. We have many stories, with several focusing on breast cancer, including male breast cancer. Pink ribbons are not just for women.
Breast CancerSurvivorship
Listening to Our Instincts
By Teresa Todt
Teresa Todt could not shake the nagging feeling that the pain in her breast was something serious, but repeated visits to her gynecologist and a mammogram didn’t lead anywhere. It was only after she found blood in her bra that additional tests showed she had invasive breast cancer.
Breast CancerPatient Stories
The Good, the Bad, and the Funny: Making the Most of a Life Shaped by Breast Cancer
By Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG
Enjoy Lillie Shockney’s sense of humor as you read her personal story of how working as a nurse and facing her own breast cancer diagnosis shaped her life and her lifelong work as a breast cancer educator and advocate.
Breast CancerImmunotherapy
A Breakthrough in the Treatment of Metastatic Triple-Negative Breast Cancer
By Erika Hamilton, MD
Recently, Tecentriq became the first immunotherapy to be approved for the treatment of patients with metastatic triple-negative breast cancer, a particularly difficult type of breast cancer.
Last modified: July 15, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country